Dr Urvish Pandya - Independent Small-Molecule CMC Leader and Chemical-Development Consultant
Dr Urvish Pandya is an independent small-molecule CMC leader, organic and process chemist, chemical-development consultant and founder of Allotrope Scientific. Clients work directly with him for strategic, fractional and hands-on support from preclinical development through GMP manufacture and commercial readiness.
He combines broad CMC programme leadership with deep expertise in drug-substance/API process development, engineering-informed scale-up, CDMO oversight, technology transfer and manufacture. His work connects chemistry with analytical understanding, equipment, engineering and operational considerations, quality, regulatory CMC, supply and commercial delivery.
Chemistry and CMC career
Urvish's career has progressed from hands-on process chemistry at Torrent Pharmaceuticals through doctoral research, academic research and teaching in India and France, technology development and commercialisation, outsourced development and manufacturing leadership, and independent consultancy.
He later headed the Aesica/Recipharm API Development Centre, leading an integrated operation spanning development laboratories, kilo-laboratory and pilot-plant capability. His responsibilities extended beyond chemistry to teams, proposals, project delivery, customer experience, budgets, revenue and P&L, including leadership of several-million-pound development programmes.
Since March 2021, Urvish has worked full-time through Allotrope Scientific. Clients engage him directly for focused investigations, project support, strategic advice or fractional CMC leadership, with additional specialist collaboration used only where a programme requires it and with the client's agreement.
Experience from laboratory to commercial plant
Urvish has worked across laboratory development, 20-50 L equipment, kilo laboratories, pilot plants, toll manufacturers and commercial manufacturing plants. This continuity across physical scales helps him recognise where mixing, heat transfer, dosing, mass transfer, isolation, equipment fit and operational practice can change process behaviour.
His experience includes moving chemistry from early development towards GMP manufacture, supporting technology transfer and commercial-plant execution, and working with both sponsor organisations and outsourced development or manufacturing partners.
Small-molecule CMC leadership
Urvish supports small-molecule programmes from preclinical development through clinical supply, Phase II/III development, registration and commercial readiness. He integrates drug-substance development with analytical, quality, regulatory, supply, manufacturing and drug-product interfaces, while working with the appropriate specialists in each discipline.
This breadth is particularly valuable to virtual and emerging biotechnology companies that need experienced leadership but do not yet require, or cannot justify, a full internal CMC organisation.
Distinctive technical depth
The foundation of Urvish's work is organic and process chemistry: understanding reactions, mechanisms, impurities, physical behaviour and the reasons a process performs as it does. He applies that foundation to route and process development, crystallisation and isolation, scale-up, CDMO execution, technology transfer, GMP manufacture and technical investigation.
He is not presented as a chemical engineer or formulation scientist. His value lies in connecting chemistry with engineering, equipment and operational considerations and in leading integrated programmes alongside engineers, analytical scientists, formulation specialists, quality teams, regulatory colleagues and manufacturing organisations.
Innovation monitoring and cross-sector perspective
Alongside his consultancy work, Urvish serves as a Monitoring Service Provider for Innovate UK. He has monitored more than 50 funded innovation projects across multiple competitions and sectors, reviewing progress against technical, commercial, financial and delivery milestones.
This experience gives him a broad, current perspective on emerging technologies and the practical factors that help ambitious innovations progress from concept towards implementation. It complements his depth in chemistry and CMC with an informed cross-sector view of innovation strategy, programme execution and the evolving state of the art.
Ways to engage
Clients can engage Urvish for a focused technical investigation, a defined development or technology-transfer project, independent CDMO oversight, strategic advisory support or fractional CMC leadership. The starting point is a confidential discussion of the programme stage, immediate challenge, available evidence and the decisions that need to be made.